Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Final Appraisal Favors Cost-Effectiveness Of Aromatase Inhibitors

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K's National Institute for Health & Clinical Excellence released a final appraisal determination Aug. 11 supporting the clinical benefit of aromatase inhibitors over tamoxifen in primary adjuvant and unplanned switch treatment of early-stage breast cancer

You may also be interested in...

Aromatase Inhibitors Cost-Effective Compared To Tamoxifen, NICE Finds

Although an overall survival advantage has not been shown, the U.K. agency recommends coverage of Arimidex, Aromasin and Femara.

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

BMS Outlines Clinical Trial Disruptions, Reassures Supply Chain Secure

The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts